Skip to content

Advertisement

  • Research article
  • Open Access
  • Open Peer Review

The occurrence of non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma among metastatic melanoma patients: an observational cohort study in Denmark

  • 1Email author,
  • 2,
  • 2,
  • 2,
  • 2 and
  • 3
BMC Cancer201616:295

https://doi.org/10.1186/s12885-016-2315-0

  • Received: 23 May 2014
  • Accepted: 4 February 2016
  • Published:
Open Peer Review reports

Abstract

Background

Inhibitors of mutant BRAF are emerging as standard of care in patients with metastatic melanoma who carry relevant oncogenic mutations. However, BRAF inhibitors are found to induce cutaneous squamous cell carcinoma (cuSCC). Population-based background rates of cuSCC and non-cutaneous squamous cell carcinoma (non-cuSCC) in the metastatic melanoma population may contextualize safety signals from randomized clinical trials or the clinics. However, these background rates are lacking.

Methods

We conducted a historical cohort study to evaluate the background rates of new-onset non-melanoma skin lesions and non-cuSCC among 2,814 metastatic malignant melanoma patients diagnosed in 1997–2010, identified through the Danish Cancer Registry and the National Pathology Registry. Patients were excluded if they had a history of cancer before the metastatic melanoma diagnosis, other than skin cancers. We determined the incidence of non-melanoma malignant skin lesions and non-cuSCC that occurred post metastatic melanoma diagnosis, censoring patients at death, emigration, or December 31, 2011 (end of study period), whichever came first.

Results

The median age at metastatic melanoma diagnosis was 64 years. Over 40 % of patients died within one year of metastatic diagnosis and ~70 % died within 5 years. The percentages of patients with prior history or prevalent disease at metastatic melanoma diagnosis included: 8.6 % with cuSCC or basal cell carcinoma (BCC), 3.9 % with actinic keratosis (AK), and 0.7 % with Bowen’s disease. No patients had past or current non-cuSCC per study exclusion criterion. The incidence of non-melanoma skin lesions during the 6 months post-metastatic melanoma diagnosis was as follows: BCC, 1.8 % (42.5 per 1000 person-years [PY]); AK, 0.8 % (18.6 per 1000 PY); cuSCC, 0.1 % (1.7 per 1000 PY); Bowen’s disease, 0.04 % (0.8 per 1000 PY); and keratoacanthoma (KA), 0 %. Non-cuSCC was observed in 3 patients (0.1 %; 2.5 per 1000 PY) at 3 sites: bronchi, heart and lung.

Conclusion

CuSCC and non-cuSCC were rare events among metastatic melanoma patients.

Keywords

  • Incidence
  • Cutaneous melanoma
  • Basal-cell carcinoma (BCC)
  • Cutaneous squamous-cell carcinoma (cuSCC)
  • Bowen’s disease
  • keratoacanthoma (KA)
  • Actinic keratosis (AK)
  • Non-cutaneous squamous-cell carcinoma (non-cuSCC)
  • Population-based
  • Danish Cancer Registry
  • National Pathology Registry

Background

The incidence of cutaneous melanoma has been rising during the last four decades in white populations worldwide [1]. Although it is highly curable with surgery if detected in its earliest stages, prognosis for metastatic cutaneous melanoma patients has been historically poor, with a median overall survival in the range of 6–10 months. This poor survival was due to limited treatment options and efficacy - mainly alkylating agents, dacarbazine and temozolomide, and immunotherapy with IL-2 and/or interferon-alpha (IFN-α) [2]. Recently, treatment with immunotherapy or inhibition of the mitogen-activated protein kinase (MAPK) pathway has demonstrated clinical benefit by prolonging OS and progression-free survival (PFS) in randomized trials [37].

However, non-melanoma skin cancers — well-differentiated cutaneous squamous-cell carcinomas (cuSCC) and keratoacanthomas (KA) — have developed in approximately 11 % to 30 % of patients treated with type I BRAF inhibitors such as dabrafenib and vemurafenib [3, 812]. The incidence of cuSCC in vemurafenib-treated patients was 24 % and mostly occurred early in the course of treatment, with a median time to the first appearance of 7 to 8 weeks [8]. Approximately one third of the patients who experienced cuSCC had more than 1 event, with a median time of 6 weeks between occurrences. Potential risk factors associated with cuSCC for those vemurafenib-treated patients have been shown to be older age (≥65 years), prior skin cancer, and chronic sun exposure. A prospective observational study of patients enrolled in the phase I ⁄II clinical trials of dabrafenib revealed 18 cuSCCs occurred in eight out of 41 patients (20 %) [10]. Patients who developed cuSCCs were substantially older than the rest of the study population (median age 62 vs. 40 years). Most cuSCCs (77 %) appeared between weeks 6 and 24 following commencement of therapy on both sun-damaged and non-sun-damaged skin.

It is well established that actinic keratoses (AKs) are premalignant lesions that can progress to cuSCCs at a rate of approximately 10 % per year [13, 14]. Similar to AKs, KAs may also belong to a spectrum of premalignant lesions that can transform into cuSCC over time [15]. The histologic similarities of KAs and cuSCCs, including infiltration and cytologic atypia [13, 1619], and the reports of KAs metastasizing also support the idea that KAs are a type of well differentiated cuSCC [17, 20].

The background rates of incident malignant skin lesions among melanoma patients are lacking in the literature. Such data will help to contextualize emergent safety signals observed in clinical trials or the clinics among metastatic melanoma patients. We therefore examined the incidence rates of non-melanoma malignant skin lesions and non-cuSCC in a population-based study of metastatic melanoma patients in Denmark.

Methods

Study design

This was a historical observational cohort study among patients diagnosed with metastatic (stage IV) melanoma, based on prospectively collected data obtained from population-based medical databases in Denmark. According to Danish legislation, purely registry-based studies do not need permission from an ethical board. Our study was approved by the Danish Data Protection Agency (Jr no 2009-41-3653). Moreover, we were granted permission to abstract information from the medical files without obtaining informed consent by the National Board of Health.

The Danish National Health Service provides tax-supported health care for all inhabitants of Denmark. The Danish Cancer Registry (DCR) established in 1943 contains records of all incident cancers diagnosed in living patients or identified through autopsy. The 10th revision of the International Classification of Diseases (ICD-10) has been used to code tumors since 1978. DCR files include information on cancer type, site, morphology, and cancer history. It has been found to have a high degree of completeness [21, 22] and the proportion of morphologically verified tumors is 89 % [23]. The National Pathology Registry (NPR), which has been nationwide since 1997, contains data on type of pathological specimens, procedures, pathological tests and results, and the diagnoses assigned. Diagnoses are coded according to the SNOMED classification. The Danish Civil Registration System (CRS) has recorded data on residency, vital status, and marital status for the entire Danish population since 1968 [24]. The data on death (yes/no) are more than 99 % complete and very accurate [25].

Study population

We identified all patients (age ≥18 years) diagnosed with metastatic (stage IV) melanoma from 1997 to 2010 in Denmark. Eligible patients included those who had initial diagnoses of metastatic (stage IV) cutaneous melanoma during 1997 to 2010 and those who had earlier stage melanoma at initial diagnosis who then progressed to metastatic (stage IV) melanoma during 1997 to 2010. Only those who had melanoma as their first primary cancer were included. Patients were excluded if they had a history of cancer, other than melanoma, basel-cell carcinoma (BCC), cuSCC, Bowen’s disease, AK and KA, before the metastatic melanoma diagnosis.

Metastatic melanoma patients were identified using two national databases ― the DCR and the NPR, based on the ICD-10 Diagnosis Code and SNOMED Morphology Codes (Appendix). The DCR documents the initial diagnoses of all primary cancers; the NPR captures a large number of metastatic melanomas identified during the follow-up post initial melanoma diagnosis, although it is not 100 % complete. The index date for a patient was defined as the date of metastatic melanoma diagnosis. The Danish Civil Registration Number, a unique identification number assigned to every Danish citizen at birth or immigration, was used to link the DCR and NPR to the CRS for obtaining data on patient demographics, medical history, immigration, and death. All metastatic melanoma patients were followed until death, emigration, or end of study period, i.e., December 31, 2011.

Outcome definitions and measures

Overall survival status for these patients was described at 3, 6, 12, 36, and 60 months after metastatic melanoma diagnosis. Non-melanoma malignant skin lesions and non-cutaneous squamous-cell carcinoma were identified over the continuous intervals of 1, 2, 3, 6, 9, and 12 months after the index date, and over the total follow-up. Events of cuSCC, BCC, Bowen’s disease, AK, and KA were identified with SNOMED codes (Appendix), with restriction to the non skin topology site.

Validation of metastatic melanoma diagnosis in the NPR

Medical charts were reviewed for a random sample of 65 metastatic melanoma patients, with a registration of metastatic melanoma (including lymph node metastases) in the NPR. Of these, 40 (62 %) patients were admitted to Department of Oncology in Aarhus and 25 (38 %) patients were admitted to the Department of Plastic Surgery in Aalborg. Medical records for one patient from Aalborg could not be located. Of the remaining 64 patients, all had metastatic cutaneous melanoma according to the medical records, yielding a positive predictive value (PPV) of 100 % (95 % confidence interval [CI]: 96.2-100.0).

Statistical analysis

Mean, standard deviation, median, and range were derived for continuous variables, and number and proportion were described for categorical variables. All patients were followed from date of metastatic melanoma diagnosis until death, migration out of Denmark, or the end of study period (i.e., December 31, 2011). Kaplan-Meier survival curves were derived to describe time to death over the 3, 6, 12, 36, and 60 months after metastatic melanoma diagnosis. Patients were considered as censored if they were lost during the follow-up or if there was no enough follow-up time allowed at the end of the study period. Mortality rate and the CIs were calculated using the method outlined by Simon et al. [26].

We described the number and proportion (and 95 % CI) of patients with a history or pre-existing non-melanoma malignant skin lesions (i.e., BCC, cuSCC, Bowen’s disease, AK and KA, eligible) prior to metastatic melanoma diagnosis. None of these melanoma patients had a history or pre-existing non-cuSCC, by study design.

To be consistent with most clinical trial studies, for the current study, the incidence analysis on non-melanoma malignant skin lesions was first conducted among patients regardless of whether they had a history or pre-existing non-melanoma malignant skin lesions. The incidence analysis was further conducted among patients who had no history or pre-existing non-melanoma malignant skin lesions. The incidence analysis of non-cuSCC was conducted among all eligible patients. The sites of non-cuSCC were described. We described cumulative incidence in proportion, and incidence rate in person-year of non-melanoma malignant skin lesions (or non-cuSCC) over the continuous intervals of 0–1, 0–2, 0–3, 0–6, 0–9, 0–12 months (i.e., 0–30, 0–60, 0–90, 0–180, 0–270, 0–365 days), and over the total follow-up, following metastatic melanoma diagnosis. The numerator was the number of metastatic melanoma patients with non-melanoma malignant skin lesions (or non-cuSCC) occurring during the specified time period post metastatic melanoma diagnosis. For the determination of cumulative incidence, the denominator was the number of eligible metastatic melanoma patients. For the determination of incidence rate, the denominator was the total person-years of eligible metastatic melanoma patients, with the person-year for each patient calculated as the time from metastatic melanoma diagnosis to date of the event, death, last contact, or end of the study period, whichever occurred first. The incidence analyses were further stratified by age at diagnosis (18- < 65, 65- < 75, 75- < 85, and 85+ years).

All analyses were further stratified and compared between two subgroups, patients with metastatic disease at initial diagnosis and patients diagnosed with early stage melanoma initially who then progressed to metastatic stage during the follow-up. All analyses were done using SAS 9.2 software (Cary, NC, USA).

Results

During 1997–2010, 3,669 metastatic (stage IV) melanoma patients were identified from the DCR and NPR, including 855 (23 %) patients with a history of cancer, other than cutaneous melanoma, BCC, cuSCC, Bowen’s disease, AK, and KA, before the metastatic melanoma diagnosis (Table 1). Compared to patients with a history of cancer, those without a history of cancer (n = 2,814) were younger (median age = 64 vs. 69 y) at metastatic melanoma diagnosis. A greater proportion of patients with a history of cancer died (87.6 %) with a median time to death of 5.7 months, compared to those without a history of cancer (74.4 %, median time to death = 9.7 months).
Table 1

Patient characteristics: comparison between those with (excluded) and without (included) prior history of cancera

 

With a history of cancer

Without a history of cancer

 

N

%

N

%

Total N

855

100.0

2814

100.0

Age (y) at diagnosisb

  

 Mean (SD)

67.9 (12.9)

63.3 (15.4)

 Median (range)

69 (27–96)

64 (19–103)

Male

425

49.7

1540

54.7

Born in Denmark

836

97.8

2727

96.9

Site of metastasisb

    

 Skin

289

33.8

1527

54.3

 Soft tissue

36

4.2

166

5.9

 Liver

215

25.1

115

4.1

 Lung

35

4.1

89

3.2

 GI Tract

38

4.4

64

2.3

 Brain

35

4.1

59

2.1

 Bone

16

1.9

39

1.4

 Salivary gland

12

1.4

34

1.2

 Mamma

10

1.2

28

1.0

 Cytology, pleura

4

0.5

17

0.6

 Mucous membrane

6

0.7

6

0.2

 Gallbladder/Pancreas

2

0.2

5

0.2

 Vulva

4

0.5

5

0.2

 Unspecified or unknown

153

17.9

660

23.5

Deathb

749

87.6

2093

74.4

 Time (mo) to deathb, Median (range)

5.7 (0–156)

9.7 (0–176)

a Patients were excluded if they had a history of cancer, other than melanoma, basal cell carcinoma, cutaneous squamous cell carcinoma, Bowen’s disease, actinic keratoses, and keratoacanthoma, before the metastatic melanoma diagnosis

bP-value < 0.0001 for age at diagnosis (T-test), time to death (Wilcoxon rank sum test), number of death and site of metastasis (Chi-squared test)

Of 2,814 metastatic melanoma patients who had no history of cancer (i.e., other than cutaneous melanoma, BCC, cuSCC, Bowen’s disease, AK and KA), 1,313 (47 %) patients were initially diagnosed with stage IV melanoma, and 1,501 (53 %) patients were initially diagnosed with earlier stage melanoma and then progressed to stage IV at a later date (Table 2). Over time from 1997 to 2010, the proportion of patients with stage IV melanoma as the initial diagnosis decreased from 64.8 % to 40.6 %. Of these, 2,093 (74 %) patients died during the observation period (by December 31, 2011) and the overall mortality rate was 289.2 (95 % CI: 277.1-301.9) per 1000 person-years (PY). Among those who died, the median duration from metastatic disease diagnosis to death was 8.6 months for those diagnosed initially with stage IV melanoma and 10.6 months for those who progressed to stage IV at a later date.
Table 2

Characteristics for eligible metastatic melanoma patients who had no history of cancera

 

Overall

Stage IV at initial diagnosis

Progressed to stage IV

 

N

%

N

%

N

%

Total N

2814

100.0

1313

100.0

1501

100.0

Year at diagnosisb

      

 1997-2000

596

21.2

386

64.8

210

35.2

 2001-2005

1015

36.1

438

43.2

577

56.8

 2006-2010

1203

42.8

489

40.6

714

59.4

Age (y) at diagnosis

   

 Mean (SD)

62.8 (15.4)

63.2 (14.9)

62.4 (15.9)

 Median (range)

64 (19–103)

64 (21–97)

63 (19–103)

 18- < 40 yrs

240

8.5

101

7.7

139

9.3

 40- < 55 yrs

561

19.9

249

19.0

312

20.8

 55- < 65 yrs

669

23.8

327

24.9

342

22.8

 65- < 75 yrs

629

22.4

292

22.2

337

22.5

 75- < 85 yrs

536

19.0

270

20.6

266

17.7

 85+ yrs

179

6.4

74

5.6

105

7.0

Maleb

1540

54.7

679

51.7

861

57.4

Born in Denmark

2727

96.9

1269

96.6

1458

97.1

Site of metastasisb

      

 Skin

1527

54.3

515

39.2

1012

67.4

 Soft tissue

166

5.9

69

5.3

97

6.5

 Liver

115

4.1

47

3.6

68

4.5

 Lung

89

3.2

37

2.8

52

3.5

 GI Tract

64

2.3

33

2.5

31

2.1

 Brain

59

2.1

21

1.6

38

2.5

 Bone

39

1.4

19

1.4

20

1.3

 Salivary gland

34

1.2

10

0.8

24

1.6

 Mamma

28

1.0

15

1.1

13

0.9

 Cytology, pleura

17

0.6

8

0.6

9

0.6

 Gallbladder/Pancreas

5

0.2

3

0.2

2

0.1

 Vulva

5

0.2

3

0.2

2

0.1

 Mucous membrane

6

0.2

4

0.3

2

0.1

 Unspecified or unknown

660

23.5

529

40.3

131

8.7

Deathb

2093

74.4

1003

76.4

1090

72.6

 Time (mo) to deathb, median (range)

9.7 (0–176)

8.6 (0–176)

10.6 (0–160)

Mortality rates (95 % CI), per 1000 person-years

289.2

(277.1 – 301.9)

303.2

(285.0 – 322.5)

277.5

(261.5 – 294.4)

aPatients were excluded if they had a history of cancer, other than melanoma, basal cell carcinoma, cutaneous squamous cell carcinoma, Bowen’s disease, actinic keratosis and keratoacanthoma, before the metastatic melanoma diagnosis

bChi squared test P value: year at diagnosis (<0.0001), gender (0.003), site of metastasis (<0.0001) and number of death (0.02); Wilcoxon rank sum test P-value: time to death (<0.05)

The Kaplan-Meier curve (Fig. 1) illustrates the overall survival for patients with metastatic cutaneous melanoma. The overall 1-year survival was 58 % (95 % CI: 56 %-59 %) among 2,814 patients. The 1-year survival was slightly lower among patients who were diagnosed with stage IV melanoma initially (54 %, 95 % CI: 52 %-57 %), compared to those who had initially early stage melanoma and progressed to stage IV at a later date (60 %, 95 % CI: 58 %-63 %). The 5-year survival was 26 % (95 % CI: 24 %-28 %) overall, 25 % (95 % CI: 22 %-27 %) for patients who were diagnosed with stage IV melanoma initially, and 27 % (95 % CI: 25 %-30 %) for those who had initially early stage melanoma and progressed to stage IV at a later date.
Fig. 1
Fig. 1

Kaplan Meier overall survival curve for metastatic melanoma patients post metastatic disease diagnoses. Figure Legend: Figure 1 shows the overall survival (in months) after onset of metastatic melanoma, presented for all patients, patients with Stage IV melanoma at initial diagnosis, and patients who had initial earlier stage melanoma then progressed to stage IV melanoma. The numbers of patients at risk at 0, 3, 6, 12, 36, and 60 months for each of these three groups are shown in the table immediately below the survival curves

Of the 2,814 metastatic melanoma patients with no prior history of other cancers, 8.6 % (95 % CI: 7.6 %-9.7 %) had a history or pre-existing cuSCC or BCC, 3.9 % (95 % CI: 3.2 %-4.6 %) had a history or pre-existing AK, and less than 1 % of these patients had a history or pre-existing Bowen’s disease or KA at metastatic melanoma diagnosis (Table 3). Patients who had initial early stage melanoma who progressed to stage IV disease at a later date had a higher prevalence of SCC/BCC (10.7 %; 95 % CI: 9.2 %-12.4 %) and AK (4.9 %; 95 % CI: 3.9 %-6.0 %) than those who had stage IV metastatic melanoma at initial diagnosis (SCC/BCC, 6.2 %, 95 % CI: 5.0 %-7.7 %; and AK, 2.7 %, 95 % CI: 2.0 %-3.7 %).
Table 3

History or pre-existing non-melanoma malignant skin lesions prior to metastatic melanoma diagnosisa

Outcome

Overall (N = 2814)

Stage IV at initial diagnosis (N = 1313)

Progressed to stage IV (N = 1501)

n

% (95 % CI)

n

% (95 % CI)

n

% (95 % CI)

cuSCC or BCC

243

8.6 (7.6-9.7)

82

6.2 (5.0-7.7)

161

10.7 (9.2-12.4)

Bowen’s disease

21

0.7 (0.5-1.1)

11

0.8 (0.4-1.4)

10

0.7 (0.3-1.2)

KA

19

0.7 (0.4-1.0)

9

0.7 (0.3-1.2)

10

0.7 (0.3-1.2)

AK

109

3.9 (3.2-4.6)

36

2.7 (2.0-3.7)

73

4.9 (3.9-6.0)

aAbbreviation: BCC, basal cell carcinoma; cuSCC, cutaneous squamous cell carcinoma; AK, actinic keratosis; and KA, keratoacanthoma

The cumulative incidence and incidence rates (Table 4) of non-melanoma malignant skin lesions are presented for all metastatic melanoma patients, including those who had a history of or pre-existing non-melanoma malignant skin lesions. Four patients died on the index date, thus leaving 2,810 patients for the incidence analysis. During the first 6 months post diagnosis, the cumulative incidence (and incidence rate) for all metastatic melanoma patients was 0.1 % (1.7 per 1000 PY) for cuSCC, 1.8 % (42.5 per 1000 PY) for BCC, 0.04 % (0.8 per 1000 PY) for Bowen’s disease, 0 % for KA and 0.8 % (18.6 per 1000 PY) for AK. The incidence analyses were then repeated among those with no history or pre-existing non-melanoma malignant skin lesions (N = 2,496). Of those, the cumulative incidence (and incidence rate) for all metastatic melanoma patients was 0 % for cuSCC and KA, 1.0 % (22.8 per 1000 PY) for BCC, 0.04 % (0.9 per 1000 PY) for Bowen’s disease, and 0.5 % (12.3 per 1000 PY) for AK. Of metastatic melanoma patients who had history or pre-existing skin lesion, the cumulative incidence (and incidence rate), during the first 6 months post diagnosis, was 0.6 % (15.5 per 1000 PY) for cuSCC, 8.3 % (212.3 per 1000 PY) for BCC, 0 % for Bowen’s disease and KA, and 2.9 % (70.7 per 1000 PY) for AK. Compared with those with no history or pre-existing skin lesion, the incidence of cuSCC, BCC and AK were higher, although these results were based on the small number (N = 314) of metastatic melanoma patients who had history or pre-existing skin lesion. We observed virtually no differences in cumulative incidence or incidence rate of non-melanoma malignant skin lesions between patients who were initially diagnosed with metastatic melanoma and those who were initially diagnosed with early stage melanoma and then progressed to stage IV at a later date.
Table 4

Cumulative incidence and incidence rate of non-melanoma malignant skin lesions among patients with metastatic melanomaa

Outcome

Event, n

Cumulative Incidenceb (95 % CI)

Incidence Rateb (95 % CI)

Among all patients (N = 2810 c , regardless of whether they had a history or pre-existing skin lesion)

CuSCC

   

 Within 30 d after the index date

0

--

--

 Within 60 d after the index date

1

0.04 (0.004-0.2)

2.3 (0.3-16.2)

 Within 90 d after the index date

2

0.1 (0.02-0.2)

3.1 (0.8-12.5)

 Within 180 d after the index date

2

0.1 (0.02-0.2)

1.7 (0.4-6.7)

 Within 270 d after the index date

4

0.1 (0.05-0.3)

2.4 (0.9-6.4)

 Within 365 d after the index date

7

0.2 (0.1-0.5)

3.3 (1.6-7.0)

 Ever post index date

26

0.9 (0.6-1.3)

3.7 (2.5-5.4)

BCC

   

 Within 30 d after the index date

15

0.5 (0.3-0.9)

66.7 (40.2-110.6)

 Within 60 d after the index date

26

0.9 (0.6-1.3)

59.6 (40.5-87.5)

 Within 90 d after the index date

30

1.1 (0.7-1.5)

47.1 (33.0-67.4)

 Within 180 d after the index date

50

1.8 (1.3-2.3)

42.5 (32.2-56.1)

 Within 270 d after the index date

59

2.1 (1.6 - 2.7)

36.0 (27.9- 46.4)

 Within 365 d after the index date

68

2.4 (1.9 - 3.0)

32.9 (25.9- 41.7)

 Ever post index date

140

5.0 (4.2 - 5.8)

21.0 (17.8- 24.8)

Bowen’s disease

   

 Within 30 d after the index date

0

--

--

 Within 60 d after the index date

0

--

--

 Within 90 d after the index date

0

--

--

 Within 180 d after the index date

1

0.04 (0.004-0.2)

0.8 (0.1-6.0)

 Within 270 d after the index date

3

0.1 (0.03-0.3)

1.8 (0.6-5.6)

 Within 365 d after the index date

3

0.1 (0.03-0.3)

1.4 (0.5-4.4)

 Ever post index date

9

0.3 (0.2-0.6)

1.3 (0.7-2.4)

KA

   

 Within 30 d after the index date

0

--

--

 Within 60 d after the index date

0

--

--

 Within 90 d after the index date

0

--

--

 Within 180 d after the index date

0

--

--

 Within 270 d after the index date

1

0.04 (0.004-0.2)

0.6 (0.1-4.3)

 Within 365 d after the index date

3

0.1 (0.03-0.3)

1.4 (0.5-4.4)

 Ever post index date

10

0.4 (0.2-0.6)

1.4 (0.8-2.6)

AK

   

 Within 30 d after the index date

7

0.2 (0.1-0.5)

31.1 (14.8-65.2)

 Within 60 d after the index date

13

0.5 (0.3-0.8)

29.7 (17.2-51.1)

 Within 90 d after the index date

17

0.6 (0.4-0.9)

26.6 (16.5-42.8)

 Within 180 d after the index date

22

0.8 (0.5-1.2)

18.6 (12.2-28.2)

 Within 270 d after the index date

33

1.2 (0.8-1.6)

20.0 (14.2-28.1)

 Within 365 d after the index date

41

1.5 (1.1-2.0)

19.6 (14.4-26.6)

 Ever post index date

91

3.2 (2.6-3.9)

13.3 (10.8-16.3)

Among patients who had no history or pre-existing skin lesion (N = 2496)

cuSCC

   

 Within 30 d after the index date

0

--

--

 Within 60 d after the index date

0

--

--

 Within 90 d after the index date

0

--

--

 Within 180 d after the index date

0

--

--

 Within 270 d after the index date

1

0.04 (0.004-0.2)

0.7 (0.1-4.8)

 Within 365 d after the index date

3

0.1 (0.03-0.3)

1.6 (0.5-4.9)

 Ever post index date

17

0.7 (0.4-1.1)

2.7 (1.7-4.3)

BCC

   

 Within 30 d after the index date

10

0.4 (0.2-0.7)

49.9 (26.9-92.8)

 Within 60 d after the index date

14

0.6 (0.3-0.9)

36.0 (21.3-60.7)

 Within 90 d after the index date

15

0.6 (0.4-1.0)

26.4 (15.9-43.8)

 Within 180 d after the index date

24

1.0 (0.6-1.4)

22.8 (15.3-34.0)

 Within 270 d after the index date

27

1.1 (0.7-1.5)

18.3 (12.6-26.7)

 Within 365 d after the index date

30

1.2 (0.8-1.7)

16.1 (11.3-23.1)

 Ever post index date

77

3.1 (2.5-3.8)

12.5 (10.0-15.7)

Bowen’s disease

   

 Within 30 d after the index date

0

--

--

 Within 60 d after the index date

0

--

--

 Within 90 d after the index date

0

--

--

 Within 180 d after the index date

1

0.04 (0.004-0.2)

0.9 (0.1-6.7)

 Within 270 d after the index date

1

0.04 (0.004-0.2)

0.7 (0.01-4.8)

 Within 365 d after the index date

1

0.04 (0.004-0.2)

0.5 (0.1-3.8)

 Ever post index date

5

0.2 (0.1-0.4)

0.8 (0.3-1.9)

KA

   

 Within 30 d after the index date

0

--

--

 Within 60 d after the index date

0

--

--

 Within 90 d after the index date

0

--

--

 Within 180 d after the index date

0

--

--

 Within 270 d after the index date

0

--

--

 Within 365 d after the index date

1

0.04 (0.004-0.2)

0.5 (0.1-3.8)

 Ever post index date

6

0.2 (0.1-0.5)

0.9 (0.4-2.1)

AK

   

 Within 30 d after the index date

4

0.2 (0.1-0.4)

19.9 (7.5-53.2)

 Within 60 d after the index date

8

0.3 (0.2-0.6)

20.5 (10.3-41.0)

 Within 90 d after the index date

10

0.4 (0.2-0.7)

17.6 (9.5-32.6)

 Within 180 d after the index date

13

0.5 (0.3-0.9)

12.3 (7.2- 21.2)

 Within 270 d after the index date

19

0.8 (0.5-1.2)

12.9 (8.2-20.2)

 Within 365 d after the index date

23

0.9 (0.6-1.4)

12.3 (8.2-18.5)

 Ever post index date

53

2.1 (1.6-2.7)

8.5 (6.5-11.1)

aAbbreviation: BCC, basal cell carcinoma; cuSCC, cutaneous squamous cell carcinoma; AK, actinic keratosis; and KA, keratoacanthoma

bThe incidence analysis was conducted among 2810 patients, because 4 patients died on the index date and were excluded

cCumulative incidence, %; incidence rate, per 1000 person-years

Of 2,810 metastatic melanoma patients, 3 patients developed non-cuSCC post metastatic melanoma diagnosis. Two non-cuSCC events were identified in the heart and the bronchi, respectively, during 30–60 days post metastatic melanoma diagnosis. The third event was identified in the lung during 90–180 days post metastatic melanoma diagnosis. The cumulative incidence was 0.1 % at 6 months after the index date, corresponding to an incidence rate of 2.5 per 1000 PY (Table 5).
Table 5

Cumulative incidence and incidence rate of non-cuSCC among patients with metastatic melanomaa

Outcome

Event, n

Cumulative Incidenceb (95 % CI)

Incidence Rateb (95 % CI)

Within 30 d after the index date

0

--

--

Within 60 d after the index date

2

0.1 (0.02-0.2)

4.6 (1.1-18.2)

Within 90 d after the index date

2

0.1 (0.02-0.2)

3.1 (0.8-12.5)

Within 180 d after the index date

3

0.1 (0.03-0.3)

2.5 (0.8-7.8)

Within 270 d after the index date

3

0.1 (0.03-0.3)

1.8 (0.6-5.6)

Within 365 d after the index date

3

0.1 (0.03-0.3)

1.4 (0.5-4.4)

Ever post index date

3

0.1 (0.03-0.3)

0.4 (0.1-1.3)

aAbbreviation: non-cuSCC, non-cutaneous squamous cell carcinoma. The incidence analysis was conducted among 2810 patients, because 4 patients died on the index date and were excluded

bCumulative incidence, %; incidence rate, per 1000 person-years

We further evaluated the cumulative incidence and incidence rates of BCC and AK among metastatic melanoma patients by age at metastatic melanoma diagnosis (Table 6). Incidence rates of BCC and AK were the lowest among the youngest patients between 18–65 years at metastatic melanoma diagnosis. The incidence rates of BCC (but not AK) increased with age at metastatic diagnosis, even among those aged 65 years and above. The age-stratified analyses were not possible for cuSCC, Bowen’s disease, KA, and non-cuSCC because the numbers of these events were too small.
Table 6

Incidence rate of BCC and AK by age at metastatic melanoma diagnosisa

Outcome

18– < 65 y

65– < 75 y

75- < 85 y

85+ y

 

Nb

Rate (95 % CI)

N

Rate (95 % CI)

N

Rate (95 % CI)

N

Rate (95 % CI)

Among all patients (n = 2810 c , regardless of whether they had a history or pre-existing skin lesion)

BCC

 Within 30 d after the index date

7

59.4 (28.3-124.5)

2

39.5 (9.9-158.1)

2

46.8 (11.7-187.1)

4

291.2 (109.3-775.9)

 Within 60 d after the index date

11

47.9 (26.5-86.5)

3

30.5 (9.8-94.6)

8

97.3 (48.6-194.5)

4

151.9 (57.0-404.8)

 Within 90 d after the index date

11

32.8 (18.1-59.3)

6

41.8 (18.8-93.1)

8

66.8 (33.4-133.5)

5

131.8 (54.8-316.6)

 Within 180 d after the index date

17

27.2 (16.9-43.8)

13

49.1 (28.5-84.5)

12

55.0 (31.2-96.8)

8

118.1 (59.0-236.1)

 Within 270 d after the index date

19

21.7 (13.8-34.0)

16

43.4 (26.6-70.9)

16

52.6 (32.2-85.9)

8

87.3 (43.7-174.6)

 Within 365 d after the index date

21

18.9 (12.4-29.1)

20

43.3 (27.9-67.1)

19

49.4 (31.5-77.4)

8

71.0 (35.5- 142.0)

 Ever post index date

52

13.2 (10.0-17.3)

36

26.4 (19.1-36.6)

36

32.3 (23.3-44.8)

16

69.8 (42.7-113. 9)

AK

        

 Within 30 d after the index date

2

16.9 (4.2-67.6)

3

59.4 (19.1-184.0)

1

23.4 (3.3-165.9)

1

72.5 (10.2-515.0)

 Within 60 d after the index date

2

8.7 (2.2-34.7)

5

51.0 (21.2-122.4)

4

48.4 (18.2-129.0)

2

75.3 (18.8-301.3)

 Within 90 d after the index date

3

8.9 (2.9-27.6)

6

41.9 (18.8-93.2)

6

49.8 (22.4-110.9)

2

52.1 (13.0-208.3)

 Within 180 d after the index date

3

4.8 (1.5-14.8)

10

37.7 (20.3-70.1)

6

27.3 (12.3-60.7)

3

43.3 (14.0-134.4)

 Within 270 d after the index date

4

4.5 (1.7-12.1)

13

35.2 (20.4-60.5)

11

35.8 (19.8-64.7)

5

53.5 (22.3-128.5)

 Within 365 d after the index date

6

5.4 (2.4-11.9)

16

34.4 (21.1-56.1)

14

35.9 (21.3-60.6)

5

43.5 (18.1-104.5)

 Ever post index date

27

6.7 (4.6-9.7)

33

23.6 (16.8-33.3)

22

19.2 (12.6-29.2)

9

36.3 (18.9-69.7)

Among patients, who had no history or pre-existing skin lesion (n = 2496)

BCC

        

 Within 30 d after the index date

4

36.0 (13.5-96.0)

2

45.5 (11.4-181.8)

2

56.9 (14.2-227.5)

2

198.0 (49.5-791.8)

 Within 60 d after the index date

6

27.7 (12.5-61.7)

2

23.4 (5.8-93.4)

4

58.8 (22.1-156.8)

2

102.9 (25.7-411.6)

 Within 90 d after the index date

6

19.0 (8.5-42.3)

3

24.0 (7.7-74.4)

4

40.2 (15.1-107.2)

2

71.4 (17.9-285.6)

 Within 180 d after the index date

9

15.3 (8.0-29.4)

7

30.2 (14.4-63.3)

6

32.8 (14.8-73.1)

2

39.8 (10.0- 159.3)

 Within 270 d after the index date

9

10.9 (5.7-21.0)

9

27.8 (14.5-53.5)

7

27.4 (13.1-57.5)

2

29.4 (7.3-117.4)

 Within 365 d after the index date

11

10.5 (5.8-19.0)

9

22.1 (11.5-42.5)

8

24.6 (12.3-49.3)

2

23.8 (6.0-95.1)

 Ever post index date

36

9.6 (6.9-13.3)

19

15.5 (9.9-24.3)

17

17.4 (10.8-28.0)

5

28.0 (11.7-67.4)

AK

        

 Within 30 d after the index date

2

18.0 (4.5-71.9)

2

45.5 (11.4-181.9)

0

--

0

--

 Within 60 d after the index date

2

9.2 (2.3-36.9)

3

35.1 (11.3-108.8)

3

44.0 (14.2-136.4)

0

 

 Within 90 d after the index date

2

6.3 (1.6-25.3)

3

24.0 (7.7-74.4)

5

50.2 (20.9-120.7)

0

--

 Within 180 d after the index date

2

3.4 (0.8-13.6)

5

21.6 (9.0-51.9)

5

27.4 (11.4-65.7)

1

19.6 (2.8-139.4)

 Within 270 d after the index date

3

3.6 (1.2- 11.2)

7

21.6 (10.3-45.4)

8

31.3 (15.6-62.6)

1

14.5 (2.0-103.1)

 Within 365 d after the index date

5

4.8 (2.0-11.4)

8

19.6 (9.8-39.2)

9

27.7 (14.4-53.2)

1

11.8 (1.7- 83.7)

 Ever post index date

18

4.7 (3.0-7.4)

21

17.0 (11.1-26.1)

11

11.9 (6.1-20.0)

3

16.2 (5.2-50.3)

aAbbreviation: BCC, basal cell carcinoma; AK, actinic keratosis. Incidence rate, per 1000 person-years

bNumber of events

cThe analysis was conducted among 2810 patients, because 4 patients died on the index date and were excluded

Discussion

This study provides population-based background rates of non-melanoma malignant skin lesions and non-cuSCC among over 2,800 metastatic melanoma patients in Denmark. The Danish national registries are unique resources for studying non-melanoma malignant skin lesions, as these are not generally captured in most cancer registries elsewhere.

The uniformly organized Danish healthcare system allows a truly population-based design. The DCR is population-based with mandatory notification of all incident cancers by hospitals, general practitioners and practicing specialists, and has a high degree of completeness. NPR, additionally, captures a large number of metastatic melanomas identified during the follow-up post initial diagnosis. Utilizing both national databases in Denmark allowed us to include not only metastatic melanoma patients with initial diagnoses of metastatic disease, but also those who had earlier stage melanoma initially then progressed to metastatic cutaneous melanoma. Compared with most randomized clinical trials, the results obtained from this study are relatively robust, given this sample size, and the metastatic melanoma patients included in this study should be fairly representative of those patients in the clinics, as only minor inclusion and exclusion criteria were applied.

Furthermore, the data quality of DCR and NPR is high [2123]. Although the definition of diagnostic criteria or sensitivity of the diagnostic tools may have changed over time, which may explain the decrease in the proportion of patients with initial metastatic melanoma diagnosis over time, the validity measured by the proportion of morphologically verified tumors in DCR has been found to be 89 % [21], a very high proportion internationally [27]. Results from our validation of metastatic melanoma diagnosis in the NPR presented a nearly perfect positive predictive value. Therefore, we expect selection bias to be minimal. With the ability to link the DCR and the NPR to the CRS, which contains daily updated vital status of the entire Danish population, we had virtually no loss of follow-up for these patients. These national health registries in Denmark have been widely used in epidemiological studies [28]. Standard data quality checks are routinely performed and missing data and loss to follow-up are relatively minor issues for these national health registries.

This study has limitations. The completeness of the NPR is not known. Lesions that were not histological verified and were not reported to the cancer registry may have been missed, and therefore the incidence rates of non-melanoma skin lesions may be underestimated. Nonetheless, the NPR in Denmark contains all histological examinations, including those from office-based treatment facilities. Thus, our research captured most lesions with histological confirmation. An article published in 2010 by Birch-Johansen F et al. [29] showed the BCC and SCC incidence rates for Denmark in the period 1978–2007, using data from both DCR and NPR. The incidence rates reported in this paper were among the highest incidence rates ever found in a European country. The authors acknowledged that the two registries are not 100 % complete in capturing BCC/SCC, but suggest that the high rates may partially be due to a more complete registration of SCC and especially BCC in these registries compared to registries in other European countries.

We had limited statistical precision for several rare study outcomes, especially cuSCC, Bowen’s disease, KA, and non-cuSCC. This must be taken into consideration when interpreting the estimates. The results from this study may not be directly generalized to a different country, region, or ethnic group.

Conclusion

In conclusion, our results suggest that metastatic melanoma patients may further develop non-melanoma skin lesions and non-cuSCC; however, the incidence is low. Among the tumor types studied in this Danish cohort, BCC was more common, followed by AK, cuSCC, and non-cuSCC. Bowen’s disease and KA were the most rare. These background rates provide population-based context for contextualizing safety signals from the randomized clinical trials. Furthermore, these results may inform physicians and patients when similar events are observed in the clinics among metastatic melanoma patients.

Abbreviations

AE: 

adverse event

AJCC: 

American Joint Committee on Cancer

AK: 

actinic keratosis

CRS: 

the Danish Civil Registration System

BCC: 

basal-cell carcinoma

cuSCC: 

cutaneous squamous-cell carcinomas

DCR: 

the Danish Cancer Registry

ICD: 

International classification of diseases

KA: 

keratoacanthoma

MAPK: 

mitogen-activated protein kinase

Non-cuSCC: 

non-cutaneous squamous-cell carcinomas

NPR: 

the National Pathology Registry

OS: 

overall survival

PFS: 

progression-free survival

PPV: 

positive predictive value

SAS: 

Statistical Analysis Software

Declarations

Acknowledgements

The funding support for this study (WEUSKOP6139) was provided by GlaxoSmithKline. This study was conducted utilizing several national databases in Denmark, which were funded through Aarhus University Hospital.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Worldwide Epidemiology, R&D, GlaxoSmithKline, 1250 South Collegeville Rd, Collegeville, PA 19426, USA
(2)
Department of Clinical Epidemiology, Aarhus University Hospital, Olof Palmes Allé 43 – 45, Aarhus N, DK-8200, Denmark
(3)
Worldwide Epidemiology, R&D, GlaxoSmithKline, 5 Moore Drive, Research Triangle Park, NC 27709-3398, USA

References

  1. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27:3–9.View ArticlePubMedGoogle Scholar
  2. Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16:5–24.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.View ArticlePubMedPubMed CentralGoogle Scholar
  4. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367:107–14.View ArticlePubMedGoogle Scholar
  5. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380:358–65.View ArticlePubMedGoogle Scholar
  6. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol. 2013;24:2174–80.View ArticlePubMedPubMed CentralGoogle Scholar
  8. ZELBORAF Prescribing Information (USPI, United States Product Insert), in, 2011Google Scholar
  9. TAFINLAR Prescribing Information (USPI, United States Product Insert), in, 2014Google Scholar
  10. Anforth RM, Blumetti TC, Kefford RF, et al. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol. 2012;167:1153–60.View ArticlePubMedGoogle Scholar
  11. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol. 2010;28:8503. abstr.View ArticleGoogle Scholar
  12. Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: An open-label, multicenter phase II study of RG7204 (PLX4032) in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol (ASCO Annual Meeting Abstracts) 2011;29:8509.Google Scholar
  13. Clausen OP, Aass HC, Beigi M, et al. Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol. 2006;126:2308–15.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42:23–4.View ArticlePubMedGoogle Scholar
  15. Ledo E. Wart, keratoacanthoma, and squamous cell carcinoma: a spectrum of the same neoplastic process? Int J Dermatol. 1992;31:777–8.View ArticlePubMedGoogle Scholar
  16. Cribier B, Asch P, Grosshans E. Differentiating squamous cell carcinoma from keratoacanthoma using histopathological criteria. Is it possible? A study of 296 cases. Dermatology. 1999;199:208–12.View ArticlePubMedGoogle Scholar
  17. Hodak E, Jones RE, Ackerman AB. Solitary keratoacanthoma is a squamous-cell carcinoma: three examples with metastases. Am J Dermatopathol. 1993;15:332–42.View ArticlePubMedGoogle Scholar
  18. Magalhaes RF, Cruvinel GT, Cintra GF, et al. Diagnosis and follow-up of keratoacanthoma-like lesions: clinical-histologic study of 43 cases. J Cutan Med Surg. 2008;12:163–73.View ArticlePubMedGoogle Scholar
  19. Patel A, Halliday GM, Cooke BE, et al. Evidence that regression in keratoacanthoma is immunologically mediated: a comparison with squamous cell carcinoma. Br J Dermatol. 1994;131:789–98.View ArticlePubMedGoogle Scholar
  20. Goldenhersh MA, Olsen TG. Invasive squamous cell carcinoma initially diagnosed as a giant keratoacanthoma. J Am Acad Dermatol. 1984;10:372–8.View ArticlePubMedGoogle Scholar
  21. Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health. 2011;39:42–5.View ArticlePubMedGoogle Scholar
  22. Storm HH, Michelsen EV, Clemmensen IH, et al. The Danish Cancer Registry--history, content, quality and use. Dan Med Bull. 1997;44:535–9.PubMedGoogle Scholar
  23. Erichsen R, Lash TL, Hamilton-Dutoit SJ, et al. Existing data sources for clinical epidemiology: the Danish National Pathology Registry and Data Bank. Clin Epidemiol. 2010;2:51–6.View ArticlePubMedPubMed CentralGoogle Scholar
  24. Frank L, Epidemiology. When an entire country is a cohort. Science. 2000;287:2398–9.View ArticlePubMedGoogle Scholar
  25. Schmidt M, Pedersen L, Sorensen HT. The danish civil registration system as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541-549.Google Scholar
  26. Simon R. Confidence intervals for reporting results of clinical trials. Ann Intern Med. 1986;105:429–35.View ArticlePubMedGoogle Scholar
  27. Parkin DM, Chen VW, Ferlay J, Galceran J, Storm HH, Whelan SL, editors. Comparability and quality control in cancer registration. (IARC Technical Report No. 19). Lyon: IARC (WHO) and IACR; 1994Google Scholar
  28. Sorensen HT, Christensen T, Schlosser HK, et al. Use of medical databases in clinical epidemiology. Department of Clinical Epidemiology, Aarhus, Denmark: SUN-TRYK, Aarhus University; 2009Google Scholar
  29. Birch-Johansen F, Jensen A, Mortensen L, et al. Trends in the incidence of nonmelanoma skin cancer in Denmark 1978–2007: Rapid incidence increase among young Danish women. Int J Cancer. 2010;127:2190–8.View ArticlePubMedGoogle Scholar

Copyright

© Li et al. 2016

Advertisement